GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeOne Medicines Ltd (SHSE:688235) » Definitions » Cyclically Adjusted PS Ratio

BeOne Medicines (SHSE:688235) Cyclically Adjusted PS Ratio : 20.55 (As of Jun. 04, 2025)


View and export this data going back to 2021. Start your Free Trial

What is BeOne Medicines Cyclically Adjusted PS Ratio?

As of today (2025-06-04), BeOne Medicines's current share price is ¥236.98. BeOne Medicines's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was ¥11.53. BeOne Medicines's Cyclically Adjusted PS Ratio for today is 20.55.

The historical rank and industry rank for BeOne Medicines's Cyclically Adjusted PS Ratio or its related term are showing as below:

SHSE:688235' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 14.31   Med: 18.47   Max: 22.73
Current: 19.66

During the past years, BeOne Medicines's highest Cyclically Adjusted PS Ratio was 22.73. The lowest was 14.31. And the median was 18.47.

SHSE:688235's Cyclically Adjusted PS Ratio is ranked worse than
81.89% of 497 companies
in the Biotechnology industry
Industry Median: 5.61 vs SHSE:688235: 19.66

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

BeOne Medicines's adjusted revenue per share data for the three months ended in Mar. 2025 was ¥5.604. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ¥11.53 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


BeOne Medicines Cyclically Adjusted PS Ratio Historical Data

The historical data trend for BeOne Medicines's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeOne Medicines Cyclically Adjusted PS Ratio Chart

BeOne Medicines Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 15.44

BeOne Medicines Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.28 14.50 20.73 15.44 20.71

Competitive Comparison of BeOne Medicines's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, BeOne Medicines's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Cyclically Adjusted PS Ratio falls into.


;
;

BeOne Medicines Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

BeOne Medicines's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=236.98/11.53
=20.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, BeOne Medicines's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=5.604/107.7224*107.7224
=5.604

Current CPI (Mar. 2025) = 107.7224.

BeOne Medicines Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.012 100.464 0.013
201509 0.013 99.785 0.014
201512 0.074 99.386 0.080
201603 0.015 99.475 0.016
201606 0.006 100.088 0.006
201609 0.000 99.604 0.000
201612 0.000 99.380 0.000
201703 0.000 100.040 0.000
201706 0.000 100.285 0.000
201709 2.409 100.254 2.588
201712 0.203 100.213 0.218
201803 0.307 100.836 0.328
201806 0.489 101.435 0.519
201809 0.502 101.246 0.534
201812 0.523 100.906 0.558
201903 0.674 101.571 0.715
201906 2.159 102.044 2.279
201909 0.456 101.396 0.484
201912 0.506 101.063 0.539
202003 0.364 101.048 0.388
202006 0.460 100.743 0.492
202009 0.540 100.585 0.578
202012 0.554 100.241 0.595
202103 3.137 100.800 3.352
202106 0.807 101.352 0.858
202109 1.105 101.533 1.172
202112 1.103 101.776 1.167
202203 1.461 103.205 1.525
202206 1.711 104.783 1.759
202209 2.023 104.835 2.079
202212 1.964 104.666 2.021
202303 2.279 106.245 2.311
202306 3.134 106.576 3.168
202309 4.101 106.570 4.145
202312 3.348 106.461 3.388
202403 3.993 107.355 4.007
202406 4.953 107.991 4.941
202409 5.148 107.468 5.160
202412 5.902 107.128 5.935
202503 5.604 107.722 5.604

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BeOne Medicines  (SHSE:688235) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


BeOne Medicines Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of BeOne Medicines's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


BeOne Medicines Business Description

Address
c/o BeOne Medicines I GmbH, Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.

BeOne Medicines Headlines

No Headlines